
CanSino CEO Xuefeng Yu Bets on China's Vaccine Market as Pipeline Expands
In exclusive interviews, CanSino Biologics' chairman discusses first-half results, the AstraZeneca deal, and the legacy of China's Ebola vaccine.
Aug 28, 20260 views

In exclusive interviews, CanSino Biologics' chairman discusses first-half results, the AstraZeneca deal, and the legacy of China's Ebola vaccine.